The disclosure relates to compositions comprising isolated mitochondria or combined mitochondrial agents, and methods of treating or preventing disorders or damage associated with ischemia-reperfusion injury (IRI) using such compositions.

To provide a pharmaceutical composition having a novel use comprising a dental pulp-derived multipotent stem cell preparation that can be administered to humans. A pharmaceutical composition comprising dental pulp-derived stem cells as an active ingredient for suppressing infiltration into a tissue of at lease neutrophils, monocytes, or lymphocytes.

The present disclosure describes a method for the treatment of pancreatic cancer includes administering an effective amount of an MK2 inhibiting agent. In other aspects, the method may include administering the effective amount of the MK2 inhibiting agent in combination with a chemotherapy composition. In additional aspects, a composition for the treatment of pancreatic cancer is disclosed that includes an effective amount of an MK2 inhibiting agent and an effective amount of a chemotherapy composition.

As a result of dedicated studies, the present inventors succeeded in discovering, for the first time, that fibrogenesis could be suppressed at the physiological tissue level by inhibiting sulfation at position 4 or 6 of GalNAc, which is a sugar that constitutes sugar chains. Furthermore, the present inventors conducted studies using various disease model animals, and as a result, successfully demonstrated that inhibitors of sulfation at position 4 or 6 of GalNAc had therapeutic effects on diseases caused by tissue fibrogenesis (tissue fibrogenic disorders).

The present invention provides methods for treating tumors in subjects by using a recombinant interferon (rSIFN-co), and optionally, methods for treating solid tumors, such as lung cancer, among others, with or without prior surgery, and as a first line or second line monotherapy or in combination with one or more other anti-tumor therapies. The present invention further provides non-surgical methods for eliminating tumors or reducing tumor sizes in subjects, and/or preventing postoperative tumor recurrence and/or metastases in subjects by using the recombinant interferon (rSIFN-co) which comprises a unique spatial configuration, alone or in conjunction with radiotherapy, chemotherapy, and/or one or more anti-tumor drugs such as biological agents, targeted drugs, small molecules, Traditional Chinese Medicine (TCM) and the like.

Implantable scaffolds that treat solid tumors and escape variants and that provide effective vaccinations against cancer recurrence are described. The scaffolds include genetically-reprogrammed lymphocytes and a lymphocyte-activating moiety.

The invention relates to a pharmaceutical composition of the cores of microgranules containing pancreatin, cetyl alcohol, poloxamer 407 in predetermined quantities, the production method, as well as the production of the water-based enteric-coated microgranules. Furthermore, the resulting oral dosage form does not contain residual acetone. The technical result is in achieving higher stability of the cores and the enteric-coated microgranules, respectively, while maintaining the good solubility of the enteric-coated microgranules, which allows the application of the claimed pancreatin microgranules for the preparation of safe and non-toxic drugs for the treatment of digestive disorders.

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

Pharmaceuticals compositions comprising the 2S,4R, ketoconazole enantiomer or its pharmaceutically acceptable salts, hydrates, and solvates, that are substantially free of the 2R,4S ketoconazole enantiomer are useful to reduce cortisol synthesis and for the treatment of type 2 diabetes, hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and other diseases and conditions, including but not limited to Cushing's Syndrome, depression, and glaucoma.

The present invention provides compositions and methods for enhancing beta cell maturation, health and function. The invention may be used for increasing insulin secretion in a cell, promoting the formation of cell clusters, or reducing cell death. In some embodiments, the compositions and methods provide a treatment for diabetes. In some embodiments, the composition comprises an agent which increases a β-cell surface protein expression, activity or both.